Search

A questionnaire was sent to Dutch neurosurgeons and neurologists in order to assess current management strategies for cerebellar hematoma. Seven patients were presented, using as determinants: size of hematoma, coma score, interval to clinical deterioration, hydrocephalus, comorbidity, anticoagulant treatment and age. Neurological management options were: no treatment, monitoring or referral for neurosurgery. Neurosurgical options were: no treatment, monitoring, hematoma evacuation, and/or external ventricular drainage. Ninety-seven of 161 (60%) neurologists, and 58 of 85 neurosurgeons (68%) responded. Only 20 respondents (13%) made use of a local guideline. Overall agreement was perfect in 1 case and moderate to high in the others, but chance-adjusted agreement (kappa) between pairs of neurologists and neurosurgeons who were matched for referral center was not statistically significant except in 1 case, a deeply comatose patient with a 4-cm hematoma. In an alert, slightly ataxic patient with a large (4.5-cm) hematoma, 84 neurologists (88%) decided not to refer the patient. The estimated time for transfer between centers was of no influence on this decision. We conclude that the management of cerebrellar hematoma can be improved upon by encouraging the use of local guidelines, and by promoting early referral to a center with neurosurgical facilities., (Copyright 2001 S. Karger AG, Basel)

This study was done to evaluate the effect of spinal cord stimulation (SCS) on critical limb ischemia and to report technical problems and complications. One hundred and twenty patients with critical limb ischemia were eligible for randomization between medical treatment and medical treatment plus SCS. Sixty received a spinal cord stimulator (Itrel II; Medtronic, Minneapolis, Minn., USA). Primary outcome measures were limb salvage and pain relief. The mean pain reduction in both treatment groups was 50% (from 5 to 2.5 on the visual analog scale). The 2-year limb survival was 52% (SCS) versus 46% (standard treatment; p = 0.47). The number of patients undergoing major amputations in the SCS group with intermediate TcpO2 values was half of that in the standard group (14 vs. 28; 24 vs. 48%; p = 0.17). Implantation was successful in 51 patients. Technical problems such as loss of stimulation due to lead displacement occurred in 13 patients (22%), local infection at the site of implantation occurred in 3 patients (5%), resulting in a total complication rate of 27%. Premature depletion of the battery occurred within 2 years in 3 patients (5%). There were no lead fractures, epidural infections, hematoma or cerebrospinal fluid leakage. Training of physicians and better reliability of the hardware should reduce the frequency of technical problems. Lead displacement remains the major technical problem. The search for prognostic factors of limb salvage is important. One microcirculatory measurement (TcpO2) seems to have a prognostic value, which remains to be described more precisely.